publication . Part of book or chapter of book . 2012

Anticancer Drug Metabolism: Chemotherapy Resistance and New Therapeutic Approaches

Hanane Akhdar; Claire Legendre; Caroline Aninat; Fabrice More;
Open Access English
  • Published: 22 Feb 2012
  • Publisher: InTech
Over the last decades, several studies have demonstrated that cancer cells have a unique metabolism compared to normal cells (Herling et al., 2011). Metabolic changes occurring in cancer cells are considered to be fundamental for the transformation of normal cells into cancer cells and are also responsible for the resistance to different types of chemotherapeutic drugs (Cree, 2011). Therefore, resistance to chemotherapy represents a major problem in the treatment of several tumor types. Among the different metabolic and signalling pathways that are altered in cancer cells, variations in the expression and activity of several drugmetabolizing enzymes play a criti...
free text keywords: Cancer cell, Drug resistance, Chemotherapy, medicine.medical_treatment, medicine, Enzyme, chemistry.chemical_classification, chemistry, Multiple drug resistance, Drug, media_common.quotation_subject, media_common, Drug metabolism, Pharmacology, Cross-resistance, business.industry, business
Download fromView all 2 versions
Part of book or chapter of book . 2012
Provider: InTech
Part of book or chapter of book
Provider: UnpayWall
Part of book or chapter of book . 2012
Provider: Crossref
218 references, page 1 of 15

Aas, T., Borresen, A.L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J.E., Akslen, L.A., and Lonning, P.E. (1996). Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med, Vol.2, No.7, 811-814.

Adler, V., Yin, Z., Fuchs, S.Y., Benezra, M., Rosario, L., Tew, K.D., Pincus, M.R., Sardana, M., Henderson, C.J., Wolf, C.R., Davis, R.J., and Ronai, Z. (1999). Regulation of JNK signaling by GSTp. EMBO J, Vol.18, No.5, 1321-1334.

Akhdar, H., Loyer, P., Rauch, C., Corlu, A., Guillouzo, A., and Morel, F. (2009). Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer HT-29 cells. Eur J Cancer, Vol.45, No.12, 2219-2227.

Andrei, D., Maciag, A.E., Chakrapani, H., Citro, M.L., Keefer, L.K., and Saavedra, J.E. (2008). Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities. J Med Chem, Vol.51, No.24, 7944-7952.

Baird, L., and Dinkova-Kostova, A.T. (2011). The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol, Vol.85, No.4, 241-272.

Ban, N., Takahashi, Y., Takayama, T., Kura, T., Katahira, T., Sakamaki, S., and Niitsu, Y. (1996). Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res, Vol.56, No.15, 3577-3582.

Baskin-Bey, E.S., Huang, W., Ishimura, N., Isomoto, H., Bronk, S.F., Braley, K., Craig, R.W., Moore, D.D., and Gores, G.J. (2006). Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. Hepatology, Vol.44, No.1, 252-262.

Basseville, A., Preisser, L., de Carne Trecesson, S., Boisdron-Celle, M., Gamelin, E., Coqueret, O., and Morel, A. (2011). Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol Cancer, Vol.10, No.1, 80. [OpenAIRE]

Bauer, B., Hartz, A.M., Fricker, G., and Miller, D.S. (2004). Pregnane X receptor upregulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol, Vol.66, No.3, 413-419.

Baumert, C., and Hilgeroth, A. (2009). Recent advances in the development of P-gp inhibitors. Anticancer Agents Med Chem, Vol.9, No.4, 415-436. [OpenAIRE]

Bernardini, S., Bernassola, F., Cortese, C., Ballerini, S., Melino, G., Motti, C., Bellincampi, L., Iori, R., and Federici, G. (2000). Modulation of GST P1-1 activity by polymerization during apoptosis. J Cell Biochem, Vol.77, No.4, 645-653. [OpenAIRE]

Bignami, M., Casorelli, I., and Karran, P. (2003). Mismatch repair and response to DNAdamaging antitumour therapies. Eur J Cancer, Vol.39, No.15, 2142-2149. [OpenAIRE]

Biswas, A., Mani, S., Redinbo, M.R., Krasowski, M.D., Li, H., and Ekins, S. (2009). Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res, Vol.26, No.8, 1807-1815.

Blanco-Bose, W.E., Murphy, M.J., Ehninger, A., Offner, S., Dubey, C., Huang, W., Moore, D.D., and Trumpp, A. (2008). C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology, Vol.48, No.4, 1302-1311.

Bock, K.W., Lilienblum, W., Fischer, G., Schirmer, G., and Bock-Henning, B.S. (1987). The role of conjugation reactions in detoxication. Arch Toxicol, Vol.60, No.1-3, 22-29.

218 references, page 1 of 15
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Part of book or chapter of book . 2012

Anticancer Drug Metabolism: Chemotherapy Resistance and New Therapeutic Approaches

Hanane Akhdar; Claire Legendre; Caroline Aninat; Fabrice More;